header logo image


Page 798«..1020..797798799800..810820..»

Exhibition explores a brave new world – Griffith News

November 24th, 2019 11:48 pm

A thought-provoking new exhibition by world-renowned artist Bonita Ely has opened at Griffith University Art Museum.

Bonita Ely: Future Tense explores dystopian futures wrought by environmental degradation and genetic engineering.

The major survey exhibition brings together several of Elys major works imagining an impossible future where nature has adapted with the assistance of science, and flourished despite the devastating effects of pollution and climate change.

Shown in Australia for the first time since its debut at documenta14 in 2017, Plastikus Progressus 2017/19 parodies natural history displays. Set in 2054, it features genetically-engineered creatures that consume plastic and, in the process, clean up our mess in the streets, oceans and rivers. The installation includes a new section examining the plastic pollution of the Brisbane River.

We Live to be Surprised 1989/2019 is Elys latest installation of snabbits half snail/half rabbits. Engineered as a food source for an over-populated planet, these creatures have evolved into an ominous feral monoculture.

The exhibition also includes a major 1973 painting by Ely, The Locust People, which shows Elys interest in environmental issues since the earliest years of her practice.

Director of Griffith University Art Museum Angela Goddard, who curated the exhibition, said Ely was a fascinating artist whose practice blurred the lines between art and science.

I like her intuitive way of working and projecting ideas, and how she imagines the future and how we might adapt to it, she said.

Bonita is a major figure in contemporary art and her work has great currency, as evidenced by both installations having recently been shown in EuropePlastikus Progressus in Poland and We Live to be Surprised in the UKwe are fortunate to be able to see these works here in Australia.

Griffith University Art Museum acknowledges the generosity of exhibition partners Lock, Stock and Barrel, Shut the Gate Wines and Solver Paints.

The exhibition runs until 8 February 2020 at Griffith University Art Museum, South Bank.

Read more:
Exhibition explores a brave new world - Griffith News

Read More...

The religious polarization of India – indica News

November 24th, 2019 11:48 pm

Justice Markandey Katju-

Although the Constitution of India declares India to be a secular country, the ground reality is very different. In recent years, particularly after the Hindu right wing Bharatiya Janata Party ( BJP ) came to power in 2014, Indian society has been considerably polarized on religious lines.

Consider the following facts :

It is clear that in recent years polarization of Indian society on religious basis has witnessed an exponential upsurge. Earlier too there was communal feeling, but it was largely latent, erupting only on occasions. Now under BJP rule from 2014 it has become open, virulent. and continuous. What is the cause?

Some people say that it is because of reaction among Hindus who were earlier suppressed due to appeasement policy of Congress towards Muslims who were treated as a vote bank. Others say that Muslims are inherently fanatics and bigots, who often resort to terrorism, etc. But what is the truth?

The truth is that 99% of all people, whether Hindu, Muslim, Christian, Sikh, Jain, Parsi or Buddhist are good people. Most Muslims, like most Hindus, are peaceful, upright and law abiding. So it is absurd to say that all, or even most, Muslims are bigots and terrorists.

In fact there was no communal feeling before 1857, as I have explained in my article The Truth about Pakistan published in the Pakistani newspaper The Nation some years back. Before 1857 Hindus and Muslims lived harmoniously, Hindus used to participate in Eid and Muharram, and Muslims in Holi and Diwali.

Communalism was artificially created after suppressing the 1857 Mutiny ( in which Hindus and Muslims fought together against the British ) by the British rulers as part of their divide and rule policy ( see BN Pandes History in the service of Imperialism online ), and this was continued even after Independence, but now it has increased exponentially.

There are two reasons for the recent upsurge in communal polarization in India, one internal, and the other external. Let me explain

Internal causes of polarization

The Congress Party, by its Muslim appeasement policy (to get Muslim votes ) created a strong reaction among many Hindus, who though forming 80% of the Indian population, felt they were being ignored, and all the Congress cared for was the 15% Muslims. This naturally created a backlash, which helped the BJP to come to power in 2014. Of course, the scandalous corruption by most Congress leaders and Modis vikas slogan also helped.

However, now the Indian economy is tanking, with huge dip in GDP, manufacturing sector, IT, real estate etc. on the rapid decline, and record unemployment as admitted by National Sample Survey, a Govt of India organization ( 12 million Indian youth are entering the job market every year but jobs are shrinking ), child malnourishment ( every second Indian child is malnourished, according to Global Hunger Index and UNICEF ), 50% Indian women anaemic, farmers suicides ( already well over 300,000 ) continuing unabated, almost total lack of proper healthcare and good education for the masses, etc.

The present Govt of India has no inkling how to resolve these massive problems, so to divert public attention from them it has to have a scapegoat. This scapegoat is the Muslims, who, like the Jews in the Nazi era, are blamed for all social evils. Muslims are vilified as fanatics, anti-national and terrorists. The Indian media, which has largely been Modified, dutifully obliges by spreading communal hatred.

Propaganda is such a powerful thing that even good peoples minds can be poisoned. For instance, Germans are ordinarily very good people, but during the Nazi era almost the whole German nation went mad, their minds poisoned by Hitler and Goebbels. Similarly, by the communal propaganda and other wicked techniques of the BJP most Hindus have been made Muslim haters in recent years.

Some people deny that BJP is anti-minority, and they refer to Modis statement Sabka saath, sabka vishwas but everyone knows this is hypocrisy and empty rhetoric. BJPs entire politics is based on hatred of minorities, particularly Muslims. BJP is dominated by an organization called the RSS (Rastriya Swayamsevak Sangh ), which is rabidly anti minority ( see the book Bunch of Thoughts by the former RSS leader M.S.Golwalkar). Only by spreading and increasing religious hatred can the BJP thrive.

This world really consists of two worlds, the world of the developed, highly industrialized countries ( North America, Europe, Japan, Australia, New Zealand and China ), and the world of the underdeveloped countries ( which includes India ).

The national objective of India must be to transform and uplift itself into the ranks of the developed countries, for then only can it abolish poverty, unemployment and its other massive problems.

However, this transformation will be opposed tooth and nail by the developed countries, which have an unwritten rule that underdeveloped countries must not be allowed to join the ranks of the developed countries. Why this is so needs to be explained.

Cost of labor is a big chunk of the total cost of production. So if the cost of labor is less the cost of production is less, and one can sell his product at a cheaper price and eliminate his business rival by underselling him i.e. by selling the same quality goods at a cheaper price. There is competition in the market, and one businessman eliminates another not with guns, bombs or tanks but by underselling him.

For instance, after the 1949 Revolution, the Chinese leaders built up a massive industrial base in China. That massive industrial base, coupled with the cheap labor available in China, enabled the Chinese to undersell the whole world in consumer goods. Today the supermarkets of Western countries are packed with Chinese goods, which sell at less than half the price of goods made by Western manufacturers (because the Western labor is expensive). Consequently, many Western industries, which could not face the Chinese competition, had to close down.

Now coming to India, the situation in 1947, when India became independent, was that there were then very few industries and very few engineers. This was because of the policy of the British rulers who did not want India to become an industrialized nation, and wanted to keep it backward and feudal. However, after Independence there was a limited degree of industrialization in India, a heavy industrial base (steel plants etc.) were set up, engineering colleges like IITs were established, etc. The result is that today India is very different from the India of 1947. Today it has all that is required to become a highly industrialized nationa huge pool of technical talent (its IT engineers are largely manning Silicon Valley, and American Universities are full of Indian Professors in Engineering, Science and Mathematics) and immense natural resources.

But if India in fact becomes a highly industrialized country then with its cheap labor it will undersell the Western industrial products. Our labor is even cheaper than Chinese labor, so we will even undersell the Chinese if we get highly industrialized. So, if India gets highly industrialized who will buy the expensive products of the industries of the presently developed countries? Will they not have to close down causing massive unemployment?

India is presently the most developed of the underdeveloped countries, and with correct modern minded leadership it can become a highly developed country in 15-20 years (with modern minded leaders after the Meiji Restoration of 1868 Japan took only this much time to transform itself from a feudal to a highly developed country). But if it does, will it not greatly damage the industries of the developed countries with their expensive labor?

So developed countries will strongly oppose Indias joining the ranks of the developed countries. And how do they do that? By supporting and inciting religious and caste conflicts. In other words, by making Indians fight with each other. I strongly suspect their hidden hand behind the increased religious polarization of Indian society.

[Justice Markandey Katju is former Judge, Supreme Court of India, and former Chairman, Press Council of India. The views expressed are his own.

View original post here:
The religious polarization of India - indica News

Read More...

The fountain of youth? I tested a better anti-ageing program in Switzerland – Metro.co.uk

November 24th, 2019 11:47 pm

In Switzerland we know how to make watches. We also know how to stop time, reads the giant poster in the lobby.

Im at Victoria-Jungfrau Grand Hotel and Spa in Interlaken to sample their Better Aging program and find out if you really can stop the clock and stay looking young or if such ideas are just cuckoo.

The area certainly has a feel of youthful exuberance about it when I arrive Im greeted by paragliders, their colourful canopies drifting down onto the green across from the hotel. During my stay, not a day goes by without seeing the red and yellow wings in death-defying loops.

I can watch them from my room a smart black, brown and gold chamber housing a hard double bed with two single duvets, the traditional Swiss arrangement presumably designed to prevent greedy partners from hogging the covers. Every evening theres a Swiss truffle on my pillow.

The balcony looks out towards the Bernese Alps and the snowy peaks of Jungfrau, which means young woman or maiden. The setting of my anti-ageing quest really couldnt be better.

My journey begins at Nescens Spa, a bright space with lots of natural light, candles and trailing plants.

Spa director Hans-Peter notes down my vitals and bids me stand on a body analysis machine before Im whisked off to a room with personal trainer Brigitte, an intimidatingly fit-looking 49-year-old with a blonde crop.

Its not all bad news I have more muscle than her but I have a lot of body fat (not exactly news to me). She tells me my visceral fat is of particular concern and, among other things, advises me to avoid fruit with a high sugar content such as pineapple and grapes.

The next step is easier to take a de-stressing massage using anti-ageing Nescens oil. This should smoothe the skin and boost cell recapitalisation. The massage is gentler than others Ive had, and quite relaxing, but I cant say my skin looked different afterwards.

The spa does boast outstanding relaxation areas, however. Comfortable couches with mountain views, a smart sauna and the apex of steam rooms with twinkly lights in its starry ceiling, a fountain in middle and a gentle mint scent wafting through the air.

The next morning we come at the ageing issue via exercise with a morning of gentle Pilates. Its run by another uber-fit blonde, Iris.

Then its time for a Better Aging lunch beetroot, goats cheese and orange salad followed by a delicious sea bream with basillicum and vegetables.

Usually guests on the programme stay for at least four days, during which time meals are matched to help them achieve their fitness goals but this cant be easy with a pizzeria, Sapori, as part of the hotel.

The afternoon is dedicated to more exercise a brisk 5km walk with Iris again, through woodland and along the river, emerald with glacier water.

I have the highest hopes for todays anti-ageing treatment a classic silk bliss facial using Sensai products.

My beautician, Nicole, explains how the silk in the range was previously reserved for the Emperor of Japan. Apparently the products can activate your stem cells to help remove wrinkles.

The facial begins with Sensai Silky Purifying Creamy Soap followed by a steamer to open the pores, and some seriously thorough extraction work.

Next came the Silky Purifying Silk Peeling Mask and a mud soap wash and mask, left for six minutes. Finally came four more serums and creams.

My skin looked blotchy but felt very soft afterwards like a velvety cushion. The blotchiness was gone within half an hour, replaced with a glow. The next morning I could feel a spot coming on my neck but my face was plump, smooth and even.

The next day, after a Better Aging breakfast of light bites including tomatos, olives and smoothies, Im back with Brigitte for Nescens Full Body Training. Im cheered by the sight of some pensioners in the class. How hard can it be?

Quite hard, is the answer a full-on but not unbearable 45 minutes of planks, sit ups, star jumps and stretching giant blue elastic bands.

Afterwards I reward myself with a swim in the stunning pool. The main spa has a white, black and gold theme and incredible views.

It also has a lovely outdoor jacuzzi which you swim out to, with bubble beds, jets to massage your feet and back, and a clearer look at the mountains.

At the end of my trip I was more relaxed, my skin felt smoother and I felt fitter. While I may not look younger, as someone approaching 40 Im certainly less stressed about ageing.

Victoria-Jungfrau Grand Hotel and Spa (Picture: Yvette Caster/Metro.co.uk)

Where to stay in Switzerland

Rooms at Victoria-Jungfrau Grand Hotel and Spa cost from 296 per night, with breakfast. Better Aging guests get a 50 per cent discount in high season and 25 per cent discount in low season.

The Better Aging program lasts from four days and costs from 2,499 per person, which includes treatments, personal training and meals.

I flew with Swiss Air from Heathrow to Zrich. Flights cost from 177 return.

To get to the spa I took the train from Zrich airport to Interlaken OST via Bern. Return tickets cost from 116 via Switzerland Tourism. The hotel was about five minutes from the station by taxi.

A Swiss Travel Pass offers unlimited travel throughout the rail, bus and boat network. It includes entrance to 500 museums and costs from 185.

For more on Switzerland visit http://www.MySwitzerland.com.

Where to stay in Heathrow

I stayed at the Radisson Blu Edwardian Heathrow a decadent way to extend the spa experience.

The lobby features an impressive chandelier and theres dark wood and bronzes throughout.

The hotels spa has just had a revamp, and has a relaxation area, cosy sauna, powerful jacuzzi and beautiful blue and gold steam room.

The revamped Radisson spa at the hotel (Picture: Yvette Caster/Metro.co.uk)

I loved the showers you use between each part of the spa. Im sure they would delight fellow Pratchett fans, bringing to mind the Archchancellors bathroom as they do. There were buttons for cold mist, Caribbean storm and waterfall (but thankfully no Old Faithful).

I also tried their chocolate orange massage a thorough, full body treatment. I wasnt overpowered by scent and only really noticed the mild smell of cocoa when it was applied to my chest. It left me feeling refreshed and smelling sweet.

The hotel has two places to dine, Indian restaurant Anayu and Steak and Lobster. My T-bone steak was pleasant, although the blue cheese sauce was a bit bland, while the skinny fries were deliciously seasoned.

I enjoyed chatting to Radissons virtual host, Edward. You can text him anything 24/7 order room service, ask for late checkout and enquire about hotel services. It was like having my own PA.

Rooms at Radisson Blu Edwardian cost from 76.50 per night. They are offering Stay, Park and Fly packages from 102.50 per night, including parking for trips for eight to 15 days.

Go here to see the original:
The fountain of youth? I tested a better anti-ageing program in Switzerland - Metro.co.uk

Read More...

IT will be key to precision medicine’s success in 2020 – MedCity News

November 24th, 2019 11:45 pm

Progress in genomic science has been astronomical over the past few years. In fact, the tipping point that validated the clinical significance of genetic/genomic testing is barely visible in the rearview mirror. As a result, stakeholders ranging from clinicians to regulatory agencies, to professional associations, to payers have begun championing the value that precision medicine delivers in terms of better diagnoses and more effective therapeutic interventions.

For example, in educational materials explaining incidence of dilated cardiomyopathy (DCM), the American Heart Association notes that a full third of DCM patients inherit the condition from their parents or other family members. Germline testing can identify patients with this genetic variant, leading clinicians to a faster diagnosis and earlier treatment. The Food and Drug Administration (FDA) has stated its commitment to approving targeted therapies based on genetic mutations as appropriate. Payers are beginning to issue reimbursement policies to cover the cost of genetic/genomic testing. United Healthcare, for instance, began covering pharmacogenomic panels for patients with anxiety and depression this October.

This leads us to the next great transformation necessitated by precision medicine: implementing the technology infrastructure to govern the ordering and resulting processes inherent to genomics, as well as finding ways to manage the great volumes of data generated by testing.

Precision medicine is already being pursued sporadically across many, if not most, healthcare organizations. Oncologists are likely to be ordering somatic tests to better profile patient tumors so targeted therapies can be delivered. Family practice, behavioral medicine and psychiatric departments are using pharmacogenomics to understand how well (or poorly) patients metabolize specific medications and which might trigger side effects or safety concerns. These insights allow them to prescribe the right treatment at the right dose the first time around instead of spending months on a trial-and-error approach.

Cardiovascular and neurology specialists (among others) order germline tests to help them diagnose, treat and gain new insights into many common conditions such as congestive heart failure, arrhythmias, aneurysms, epilepsy, nerve pain and dementia. Some health systems even order germline tests on all newborns so a full genetic profile is available which can be used throughout the individuals lifetime.

The value of the data being generated through these clinical pockets cannot be understated. It carries information that can be used across a multitude of care settings far into the future to help providers and specialists arrive at more accurate diagnoses faster, and identify the most effective treatment sooner. This, in turn, can help healthcare leaders move the needle to improve quality efforts and optimize revenue while reducing the risk associated with poor outcomes.

To realize full value, however, healthcare organizations must ensure genetic/genomic test results are readily available to clinicians at the point of care and in a vocabulary that makes them meaningful. Unfortunately, few health systems have invested in the IT resources that can make this possible. Currently, test results are ordered in a vacuum and results are often returned in a PDF that will be hard to access. In addition, the information is relayed in a nomenclature unfamiliar to clinicians, so they struggle to understand how to apply the results to specific patient circumstances.

Unless these concerns are addressed, healthcare will simply reenact a mistake made years ago with the advent of electronic health records: valuable data that can immediately and directly impact care will be locked in a silo, unavailable during clinical decision-making.

As the industry heads into 2020, it must make plans and take action to get ahead of this looming problem. Healthcare IT professionals must be brought to the table to help organizations strategize about their precision medicine initiatives. The key to success with this new standard of care is recognition that data generated by genetic/genomic tests can be used endlessly across the enterprise and over the long term as patient conditions change. Organizations must seek out platforms that will consume genomic test results as discrete data and integrate it with patient-specific clinical information. Likewise, the platforms must be made available within existing workflows, so clinicians can leverage it during decision making and can interrogate the data as patient conditions change and genomic science delivers new insights.

Picture: Feodora Chiosea, Getty Images

Original post:
IT will be key to precision medicine's success in 2020 - MedCity News

Read More...

The American College of Rheumatology Adds the Vectra Test to List of Recommended Disease Activity Measures for Rheumatoid Arthritis – GlobeNewswire

November 24th, 2019 11:45 pm

SALT LAKE CITY, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced that the American College of Rheumatology (ACR) has included the Vectra test in its list of recommended disease activity measures for patients with rheumatoid arthritis (RA). The new recommendations were published in the journal Arthritis Care & Research.

The publication titled 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures states that the Vectra test is among 11 disease activity measures that met a minimum standard by categorizing into disease activity states and being feasible for regular clinical use, and that Vectra was one of the five most frequently studied RA disease activity measures among 46 evaluated. Currently, there are more than 35 peer-reviewed Vectra journal publications.

We are excited that the Vectra test has been included the ACRs recommendations for disease activity measures. It will provide physicians with an additional option to evaluate their patients with RA, said Elena Hitraya, M.D., Ph.D., chief medical officer, Myriad Autoimmune. Vectra objectively measures the inflammation associated with RA and can provide valuable information to help clinicians improve treatment decisions and outcomes for patients with RA.

Three out of four rheumatologists have used Vectra and have ordered more than 900,000 tests for their patients. RA is an autoimmune disease that attacks the patients joints and often affects other organ systems, leading to significant morbidity, increased mortality and financial burden. Approximately 60 percent of people with inadequately treated RA are unable to work by a decade after its onset. The American College of Rheumatology estimates that RA affects 1.5 million people in the United States.

About VectraVectra is a multi-biomarker molecular blood test that provides an objective and personalized measure of inflammatory disease activity in patients with rheumatoid arthritis. Vectra provides unsurpassed ability to predict radiographic progression and can help guide medical management decisions with the goal of improving patient outcomes. Vectra testing is performed at a state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician five to seven days from shipping of the specimen. Physicians can receive test results by fax or the private web portal, VectraView. For more information on Vectra, please visit: http://www.vectrascore.com.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to improving clinician treatment decisions and outcomes for patients with RA; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Here is the original post:
The American College of Rheumatology Adds the Vectra Test to List of Recommended Disease Activity Measures for Rheumatoid Arthritis - GlobeNewswire

Read More...

The Secret To Longevity Could Be Genetics – Medical Daily

November 24th, 2019 11:44 pm

Japan has the worlds oldest population, with 28 percent of all citizens comprising of elderly people above the age of 65. The secret to longevity lies not only in their healthy diet and lifestyle choices, but is influenced by a specific set of genes. Yes, the reason the country has 146 people over the age of 110 (referredto as supercentenarians) is simply good genes. This factor enabled them to stave off cancer and other deadly diseases for more than a century.

A new study conducted by the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine in Japan sought to understand the genetics behind aging in supercentenarians by analyzing single-cell RNA sequencing.In the paperthat was published in the journal Proceedings of the National Academy of Sciences, the scientists investigated the immune cells of seven supercentenarians and made comparisons to the five subjects with ages between 50 and 80 years.

Researchers looked at 41,208 cells altogether from the elders with ages over 110, and 19,994 cells in the control group. The two cells part of the bodys immune response, which are B-cells and T-cells, were studied.It was found that B-cells had a lower count in the supercentenarians, while T-cells were at the same number in both groups.

However, the major finding was that supercentenarians had more of a particular subset of T-cells, namely CD4 T-cells that are capable of killing harmful cells, which wasonly possible by cytotoxic CD8 T-cells until then. In fact, 80 percent of the T-cells were composed of CD4 markers, whereas 10 to 20 percent of the T-cells had the marker in people of ages between 50 and 80.

The secret to aging may lie in your genes. Photo courtesy of Pexels

Since T-cells with CD8 markers are known to be cytotoxic, this means the CD4 markershad changed to acquire the new function, as per the researchers. This was not the case with the relatively younger subjects, this was the single most unique genetic characteristic of supercentenarians.

"This research shows how single-cell transcription analysis can help us to understand how individuals are more or less susceptible to diseases. CD4-positive cells generally work by generating cytokines, while CD8-positive cells are cytotoxic, and it may be that the combination of these two features allows these individuals to be especially healthy," Piero Carninci, IMS Deputy Director, said.

To understand the unusual phenomenon better, the researchers further studied the cells of two older participants, only to find another interesting fact about the CD4 T-cells: They had descended and multiplied from a single ancestral cell.

"We believe that this type of cells, which are relatively uncommon in most individuals, even young, are useful for fighting against established tumors, and could be important for immunosurveillance. This is exciting as it has given us new insights into how people who live very long lives are able to protect themselves from conditions such as infections and cancer," Carninci added.

Go here to read the rest:
The Secret To Longevity Could Be Genetics - Medical Daily

Read More...

Leveraging AI To Accelerate Precision Health For Longevity – Forbes

November 24th, 2019 11:44 pm

Aging Analytics Agency

Co-authoring this article with me is my colleague Dmitry Kaminskiy, at Deep Knowledge Group.

People over 50 are the fastest growing demographic group worldwide. This creates both opportunities and challenges for the global economy and healthcare systems. The Longevity Industry, which provides products and services for those aged over 50 is becoming a multi-trillion-dollar industry. There are currently 260 companies, 250 investors, 10 non-profits, and 10 research labs in the Longevity Industry in the UK alone. In the next decade, Longevity policies enacted by governments, and changes in the financial industry will transform society. Achieving small but practical results in Longevity distributed at scale will have enormous and multiplicative effects on society. Extending the functional lifespan of humans by just one year will decrease suffering for tens of millions of people and will improve the quality of life for billions of people.

Despite having more potential to increase healthy Longevity in the short term than any other sector, AI for Longevity is an underrepresented sector in the Longevity Industry. AI holds enormous potential to rapidly accelerate the implementation of longevity research and development. To address this, Ageing Research at King's (ARK) in collaboration with the Biogerontology Research Foundation, Deep Knowledge Ventures (at which Dmitry and I are Managing Partners), along with others has established the Longevity AI Consortium at Kings College London. The Consortium will use King's world-leading advances in genetics, AI and ageing research to develop advanced personalized consumer and patient care. The Consortium will help accelerate advances in Longevity using a unique academic-industry focus on preventive and personalized physical, mental and financial health. The establishment of the AI Longevity Consortium and AI Longevity Accelerator at Kings College has the potential to help make the UK the worlds leading AI for Longevity Hub and creates an opportunity for huge advances in Longevity research which will benefit people all around the world.

Over the next few years, the Longevity AI Consortium plans to expand to include centers in Switzerland, Israel, Singapore and the US. This collaborative effort involves sophisticated methods for translating advanced AI for Longevity solutions, along with the development of advanced frameworks and technologies including novel applications of life data for insurance companies, pension funds, healthcare companies, and government bodies. These new technologies and instruments at the forefront of the rising Longevity Financial Industry provide practical applications of preventive medicine and precision health.

Sophisticated Analytical Frameworks for Precision Medicine and Longevity Diagnostics, Prognostics ... [+] and Therapeutic Benchmarking.

The Longevity AI Consortium will serve as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. This represents a paradigm shift from treatment to prevention and a new frontier - from precision medicine to precision health, enabling the UK to become the leading global hub for the application of AI to Longevity and Precision Health. The Longevity AI Consortium plans to dedicate resources to R&D in other niches where the science is ahead of the funding: e.g. microbiome diagnostics and therapeutics, recent advancements and innovations in advanced cosmetics in particular. The Consortium aims to identify novel longevity and healthy ageing biomarkers, accelerate diagnosis of age-related health decline, develop personalised physical, mental and financial health to better implement and promote effective healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity, environmental exposure and financial planning.

The Longevity AI Consortium will use sophisticated and multidimensional analytical frameworks developed by Aging Analytics Agency to perform industry benchmarking in precision health and personalized preventive medicine clinics in order to construct the ideal diagnostic, prognostic and therapeutic pipeline using the most advanced market-ready methods and technologies. The Consortium will develop a comprehensive cloud computing platform to enable the development of minimum viable and most comprehensive panels of biomarkers of aging, creating an ecosystem that incentivizes the participation of doctors, clinics, data providers, AI companies and corporate partners, and which enables efficient and streamlined commercialization and clinical implementation of both validated and experimental biomarkers of ageing as a framework for the extension of national Healthy Longevity in the UK.

This mind map provides an overview of the Longevity Industry UK Landscape including 260 companies, ... [+] 250 investors, 10 non-profits, and 10 research labs. (Image source Aging Analytics Agency).

Kings College London is the logical choice of location for the first Longevity AI Consortium, due to their unique combination of resources, departments and technologies for both AI and Longevity. Kings is also an ideal location for the AI Consortium because it has dedicated divisions and resources both for AI and for Longevity. Furthermore, being located in London, it is in an ideal physical location to engage in cross-sector and industry-academic collaboration. The AI Longevity Consortium is currently designing a complementary AI Consortium for Financial Wellness which will utilize financial and behavioural data to develop products and services to enable UK citizens to maintain financial stability, social activity and psychological well-being across extended periods of Healthy Longevity.

Currently there are only three centers in the world actively working to apply AI to precision health for healthy Longevity. These include the US based Buck Institute for Research on Aging, US based Y Combinator, and the US based AI Precision Health Institute (AI-PHI) at the University of Hawaii Cancer Center. Only the AI-PHI has actually succeeded in practice. Now that the Longevity AI Consortium has been established at Kings College London, the UK can immediately leverage its existing resources, including its very well-developed AI industry and its reputation for extremely strong industry, academic, and governmental cooperative initiatives, to become the number one global hub for the application of AI to Longevity and Precision Health.

There are currently four major AI Centres for Healthcare in major industry, academic and metropolitan hubs in the UK, but none of them have a specific focus on Longevity, precision health and preventive medicine. While these centres serve as a precedent and proof-of-concept for the viability of an AI Centre for Longevity, they do not adequately address the need for a leading AI for Longevity R&D nexus within the UK capable of developing leading solutions, products and services that leverage the power of AI to implement practical, real-world product, services and solutions to extend citizens Healthy Longevity.

Sophisticated Analytical Frameworks for Precision Medicine and Longevity Diagnostics, Prognostics ... [+] and Therapeutic Benchmarking

2020 and Beyond

In 2020, following the completion of several key development milestones, the Longevity AI Consortium plans to launch an AI Longevity Accelerator Program that will serve as a much-needed bridge between startups focusing on AI for Longevity research and drug development and major UK investors. While the UKs AI and Longevity industry ecosystems are very developed individually, the number of longevity startups utilizing AI in a major way for their internal R&D is comparatively small. The potential impact presented by the synergy of these two sectors is huge. The UK government has heavily prioritized the separate sectors of AI and Longevity, including both sectors in the top 4 Industrial Strategy Grand Challenges. However, by uniting the AI and Longevity verticals in unique and convergent ways the UK could leverage the nations strengths in these industries to their maximum potential.

AI Longevity Accelerator at Kings College aims to develop an infrastructure to promote increased investments and developments in the AI for Longevity sector to provide AI for Longevity startups with relevant levels of funding. Startups selected for inclusion in the accelerator will also receive mentorship and incubation resources, and will gain access to a global network of experts in the areas of scientific R&D, business development and investment relations. The AI Accelerator will also provide startups with the tools necessary to grow, expand and evolve following their time in the Accelerator, and will equip them with the skills required to develop further through later-stage venture capital and government grants. Longevity companies that prove capable of achieving tangible results may become the next Googles, and investment firms that invest in those companies may become the SoftBanks and Vision Funds of tomorrow. AI holds enormous potential to rapidly accelerate the implementation of Longevity research and development. The establishment of the AI Longevity Consortium and AI Longevity Accelerator at Kings College has the potential to make the UK the worlds leading AI for Longevity Hub and creates an opportunity for huge advances in Longevity research which will benefit billions of people all around the world.

Click the box below for more information on the Longevity AI Consortium.

Click the box below for information on the AI Longevity Accelerator.

Click the box below for in-depth information about the Global Longevity Industry and explore a book that Dmitry and I co-authored: Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History.

See the article here:
Leveraging AI To Accelerate Precision Health For Longevity - Forbes

Read More...

Molecular Forensics World Markets to 2029 – Massive Scope for Adoption of NGS & Capillary Electrophoresis in Emerging Nations – P&T Community

November 24th, 2019 4:46 am

DUBLIN, Nov. 21, 2019 /PRNewswire/ -- The "Global Molecular Forensics Market: Focus on Product, Technology Application, End User, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

This analysis projects the market to grow at a significant CAGR of 9.09% during the forecast period, 2019-2029. The molecular forensics market generated $996.9 million in revenue in 2018, in terms of value.

With the completion of the Human Genome Project (HGP), a new wave of technologies, called next-generation sequencing (NGS) was introduced in the healthcare industry. PCR, and NGS have fundamentally changed genomics research and enabled the scientists to research extensively on the gene variants to specific molecular diagnostics and aided the development of targeted therapeutics depending on the genetic profile of an individual. The completion of the project, subsequently, created platform for the development of precision medicines.

One of the revolutionary breakthroughs which NGS has resulted in is molecular forensics. Molecular forensics involves a detailed study of individual information to identify and characterize the molecular sequences, resulting in target-based identification. This method approach based on biomarker study is perceived to be promising in driving a paradigm shift in the molecular forensics industry, facilitating the elimination of uncertainty pertaining to the trial-and-error method of medications, and certainly eliminating unnecessary healthcare spending. With sequencing being the primitive pivotal step involved in biomarker study and in the field of genetics, the development of the sequencing technologies played a crucial role in the evolution of molecular forensics.

Further remarkable advancements in the field of genomics, proteomics, molecular biology, data analytics, and technical engineering have paved the way for the development of advanced NGS-based technologies, such as SNP and STR sequencing. The impressive research on molecular technologies and biomarkers using NGS has unlocked pathways for the development of momentous various procedures such as mtDNA sequencing.

The growing demand for non-invasive diagnostic procedures enabling genetic profiling has further enhanced the requirement of NGS technologies. Acknowledging the future potential for massive growth in demand for non-invasive diagnostic procedures, several biotechnology companies such as Illumina, Inc., Thermo Fisher Scientific, and Agilent Technologies, Inc. have invested substantially to aid further developments in forensics technologies.

Key Companies in the Molecular Forensics Market

The key manufacturers who have been contributing significantly to the molecular forensics market include Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Promega Corporation, Eurofins Scientific SE, General Electric Company, Merck KGaA, LGC Limited, and Thermo Fisher Scientific Inc. among others.

Key Questions Answered in this Report

Key Topics Covered

Executive Summary

1 Research Scope and Methodology1.1 Scope of the Study1.2 Research Methodology1.3 Data Sources1.4 Assumptions and Limitations1.5 Data and Prediction Modeling

2 Market Overview2.1 Introduction2.2 Molecular Forensics Technologies and Applications2.3 Market Available for Molecular Forensics2.4 Molecular Forensics Technology Trends2.5 Regulations and Compliances

3 Competitive Landscape3.1 Mergers and Acquisitions3.2 Product Launches and Product Updates3.3 Synergistic Activities3.4 Business Expansion Activities and Others

4 Market Dynamics4.1 Overview4.2 Impact Analysis4.3 Market Drivers4.3.1 Augmentation in the Incidences of Crime4.3.2 Growth in the Biomarker Identification Market and Advancements in Molecular Forensics Techniques4.3.3 Technological Advancements in the Field of Computational Biology4.3.4 Significant External Funding for Executing Research and Development Exercises4.4 Market Restraints4.4.1 Lack of High Complexity Testing Centers4.4.2 Expensive Sequencing Procedures and Their Applications in Medical Treatments4.4.3 High Capital Requirement Hampering the Expansion of Global Reach4.5 Market Opportunities4.5.1 Massive Scope for Adoption of NGS and Capillary Electrophoresis in Emerging Nations4.5.2 Technological Advancements in Molecular Techniques and Diagnostic Tests4.5.3 Hybridization of Technologies

5 Global Molecular Forensics Market (By Product)5.1 Overview5.2 Kits and Consumables5.3 Instruments5.4 Software and Other Products

6 Global Molecular Forensics Market (By Technology)6.1 Overview6.2 Polymerase Chain Reaction (PCR)6.2.1 Real-time PCR (q-PCR)6.2.2 Digital PCR (d-PCR)6.3 Capillary Electrophoresis6.4 NGS6.4.1 SNP and STR Sequencing6.4.2 mtDNA Sequencing6.5 Mass Spectrometry6.5.1 MS6.5.2 Tandem MS6.5.3 MS-FTIR6.6 Other Technologies

7 Global Molecular Forensics Market (By Application)7.1 Overview7.2 Radioactive Toxicology7.3 Nucleic Acid Analysis7.4 Forensic Databasing7.5 Microbial Forensics7.6 Other Applications

8 Global Molecular Forensics Market, By End User8.1 Overview8.2 Law Enforcement8.3 Disaster Management8.4 Hospitals and Healthcare Providers8.5 Other End Users

9 Global Molecular Forensics Market, By Region9.1 Overview9.2 North America9.3 Europe9.4 Asia-Pacific9.5 Latin America9.6 Rest-of-the-World

10 Company Profiles10.1 Overview10.2 Agilent Technologies, Inc.10.3 Analytik Jena AG10.4 AS ONE International, Inc.10.5 BioChain Institute Inc.10.6 Bio-Rad Laboratories, Inc.10.7 Eurofins Scientific SE10.8 General Electric Company10.9 Illumina, Inc.10.10 LGC Limited10.11 MACHEREY-NAGEL GmbH & Co KG10.12 Merck KGaA10.13 Promega Corporation10.14 QIAGEN N.V.10.15 Thermo Fisher Scientific Inc.10.16 Verogen, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/gfz227

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/molecular-forensics-world-markets-to-2029---massive-scope-for-adoption-of-ngs--capillary-electrophoresis-in-emerging-nations-300962320.html

SOURCE Research and Markets

See the article here:
Molecular Forensics World Markets to 2029 - Massive Scope for Adoption of NGS & Capillary Electrophoresis in Emerging Nations - P&T Community

Read More...

Co-creator of CRISPR lectures about future applications of genome editing technology – Daily Bruin

November 24th, 2019 4:46 am

This post was updated Nov. 20 at 7:47 p.m.

A University of California professor and co-originator of genome editing technology Clustered Regularly Interspaced Short Palindromic Repeats said researchers plan to expand the technology in order to increase human applications at a campus lecture series Thursday.

Jennifer Doudna, a UC Berkeley biochemistry professor, engaged students and the greater UCLA science community during the quarterly Donald J. Cram Distinguished Lecture series.

The Cram lecture series, a quarterly departmental event, invites prominent academics in the field of chemistry to speak about their research. The series is dedicated to Donald J. Cram, who was a Nobel laureate and a chemistry professor at UCLA for over 50 years.

This fall, the series was hosted by UCLA chemistry professor and Cram Chair Patrick Harran.

Scientists use CRISPR technology, formally known as CRISPR-Cas9, to modify DNA sequences and gene functions. Cas9 is a protein that can act like molecular scissor to cut the strands of DNA.

CRISPR is studied and used by students, scientists and researchers to advance progress in the field of gene editing, in medicine and the life sciences.

The UC holds the largest CRISPR patent portfolio in the nation with 16 total patents, according to a UC Berkeley press release.

The United States Patent and Trademark Office granted the UC, along with the University of Vienna and Emmanuelle Charpentier, the director of the Max Planck Institute for Infection Biology, its 16th patent in October.

Doudnas involvement in CRISPR technology began around 2005, when a professor at UC Berkeley, Jill Banfield, invited Doudna to help her with research into the mechanism. From there, Doudna teamed up with Charpentier, who was working with a CRISPR system and its associated protein, Cas9, in 2011.

Doudna is one of the creators of the CRISPR utility for the permanent excision of harmful genes. Doudna said that she developed the idea for the CRISPR technology in 2011 in collaboration with Charpentier.

During the lecture, Doudna detailed how scientists regulate CRISPR enzymes to modify DNA.

CRISPR is a portion of the bacterial genomic sequence that acts as an adaptive immune system, Doudna said.

Bacteria encode the CRISPR system through viral infections, which allows its genome to recognize foreign DNA insertions. These DNA sequences incorporate themselves into the bacterial genome at the CRISPR locus, a genetic database of past infections.

Doudna said this locus was of unique interest to her.

Those sequences, called CRISPR, are transcribed in RNA molecules that provide the zip codes for Cas proteins, allowing them to recognize foreign DNA and cut it up, Doudna said.

Doudna and Charpentier, with the assistance of their team, were able to realize that CRISPR RNA is a 20-nucleotide sequence, which interacts with DNA in a complementary fashion.

This complementarity allows the protein to form a double-stranded break in DNA, necessitating a second RNA tracrRNA to form this functional unit, Doudna said.

And it was (biochemist) Martin Jinek in our lab who figured out that you could combine these two RNAs into a single guide RNA, Doudna said.

From this experiment, Jinek found that single guide RNAs were used by Cas9 to excise DNA at specific sites in a plasmid, a circular piece of bacterial DNA. The revelation from this was that, upon excision, DNA would repair itself in animals and plants, Doudna said.

Doudna said at the end of her talk that the system is becoming increasingly important in the field of medicine, and is currently being used at UCLA, by Donald Kohn, a professor of microbiology, immunology and molecular genetics.

Were within about five years, maybe less, from being able to make, essentially, any change to any genome in any type of cell, Doudna said.

Doudna stressed that this ability to make changes in the genome comes with bioethical responsibility for genome editing in humans.

Fourth-year biochemistry student Jeremy Shek, who attended the event, said although he had done a project that was an offshoot of CRISPR, he had not heard of the progress Doudna discussed.

It is important to be informed on advancements and progress in the field, he added.

Fourth-year bioengineering student Timothy Yu said he came to the lecture to see Doudna in person and get a more solid grasp on the methodology of CRISPR.

Lexi Omholt, a fourth-year microbiology, immunology and molecular genetics student, said that she came to the talk to understand the basis of CRISPR technology.

Jennifer Doudna was one of the reasons I chose my major, Omholt said. At that time, CRISPR came into popular knowledge, and the knockout tool was just coming into use. I am involved in a cancer lab, the Soragni Lab, that uses CRISPR-Cas9 on a regular basis.

See original here:
Co-creator of CRISPR lectures about future applications of genome editing technology - Daily Bruin

Read More...

Biology: Insect populations plummeting, and we should worry – Stock Daily Dish

November 24th, 2019 4:46 am

Steve Rissing

Jan13,2019at4:00AM Jan13,2019at10:44AM

Theres an old joke about what goes through a flys mind as it hits your windshield.

Problem is, not many insects hit windshields anymore, and we might be the butt of that joke.

Biologists have slowly realized our windshields are cleaner these days, even after long highway trips. (I first drove to Death Valley from Indiana to study ant colonies in 1974. I stopped as often for visibility as I did for fuel.)

But the windshield phenomenon, as it is known, suggests something much larger and potentially ominous is underway at the interface of modern humanity and insects. Simply put, there are fewer insects.

Join the conversation at Facebook/columbusdispatch and connect with us on Twitter

Insects are the most ubiquitous group of organisms in the world. They are the largest group of arthropods, and arthropods are 80 percent of all described animal species. Insects play dominant roles in most land-based ecosystems. They pollinate most agricultural crops, cycle nutrients and provide structural complexity and stability to natural food webs.

For some time, studies of single species have suggested that populations of iconic species such as monarch butterflies are crashing. Annual surveys of monarchs wintering in Mexico reveal population declines exceeding 80 percent over the past two decades.

Rusty patched bumblebees once thrived throughout the Midwest, including Ohio. The U.S. Fish & Wildlife Service reports that they have declined 87 percent over the past two decades. They likely live in one-tenth of 1 percent of their former range.

Detecting possible steep declines in insect populations requires long-term, broad-scale studies. Those require funding and professional expertise.

Fortunately, several long-term surveys exist. Publications based on them support what biologists are seeing through their windshields. A New York Times magazine cover story two months ago declared it the Insect Apocalypse.

A 2017 paper in the journal PLOS One reports total insect biomass in German nature reserves declined 76 percent in 27 years. A 2018 paper in the Proceedings of the National Academy of Sciences reports a 63-fold (not percent) reduction in insects captured on sticky traps on the floor of the U.S. El Yunque National Forest in Puerto Rico over the past 40 years. The authors also observed decreases in forest insect-eating birds, frogs and lizards.

Global climate change might account for the demise of insects in tropical areas such as Puerto Rico. The apparent drivers in temperate areas such as Germany are likely more complex. Those drivers include ongoing intensification of agricultural practices and pesticide use.

Making the apparent insect collapse even worse, a recent American Entomologist paper documents the disappearance of insects from college introductory biology textbooks. The authors found that a century ago, textbooks devoted 8.8 percent of their pages to insects and their interactions with humans. Textbooks published since 2000 devote less than 0.6 percent of their pages to insects, with even less emphasis on human-insect interactions.

Topics such as modern molecular genetics, exciting to instructors who adopt textbooks, crowd out topics possibly more relevant to students, especially in general education courses.

As humanity disrupts and reduces our planets natural systems, responsible citizens and the policymakers they elect eventually will need to develop policies that mitigate and respond to changes such as massive losses of insects.

This is no time to drive blindly into that future, even if our windshields are eerily clean.

Steve Rissingis a biology professor at Ohio State University.

steverissing

More here:
Biology: Insect populations plummeting, and we should worry - Stock Daily Dish

Read More...

Omega-3 fatty acids health benefit linked to stem cell… – ScienceBlog.com

November 24th, 2019 4:46 am

For years, researchers have known that defects in an ancient cellular antenna called the primary cilium are linked with obesity and insulin resistance. Now, researchers at the Stanford University School of Medicine have discovered that the strange little cellular appendage is sensing omega-3 fatty acids in the diet, and that this signal is directly affecting how stem cells in fat tissue divide and turn into fat cells.

The finding represents a missing link between two worlds that of dietary science, and that of molecular and cellular biology. Dietary studies have long found that the consumption of omega-3 fatty acids, essential fatty acids common in fish and nuts, is associated with lower risk of heart disease, stroke, arthritis and even depression.

A paper describing the research was published online Nov. 21 in Cell. The senior author is Peter Jackson, PhD, professor of microbiology and immunology and of pathology. The lead author is postdoctoral scholar Keren Hilgendorf, PhD.

Researchers in Jacksons laboratory werent looking for omega-3s when they started their research. They were only looking for the signaling molecule that fat stem cells were sensing. The molecule could have been anything: signaling pathways in cellular biology often involve esoteric molecules few people have heard of. They only knew that in rare diseases involving a defect in the primary cilium, people are always hungry, cannot stop eating and become obese and insulin resistant. So they were surprised when the signal turned out to be omega-3 fatty acids.

When we saw that the cell was responding to omega-3 fatty acids, we realized that this had changed from just a molecular biology story to a story showing the molecular biology of how diet controls stem cells , Jackson said.

The cells sense the presence of omega-3 fatty acids through a tiny, hair-like appendage called the primary cilium, an ancient structure derived from the many flagella that algae cells first used almost 1 billion years ago to move through the oceans and sense their surroundings. Over time, as single-celled organisms evolved into multicellular creatures that first swam the oceans and then crawled onto land, cells ditched most of their flagella. But most cells kept a single flagellum, the primary cilium, to use as a highly sensitive antenna; it can pick up extremely subtle signals about the world outside the cell, helping to regulate the cells function and fate.

Jackson and his colleagues found that when omega-3 fatty acids bind to a receptor called FFAR4 on the cilia of fat stem cells, it prompts the fat stem cells to divide, leading to the creation of more fat cells. This provides the body with more fat cells with which to store energy, something that is healthier than storing too much fat in existing fat cells. What you want is more, small fat cells rather than fewer, large fat cells, Jackson said. A large fat cell is not a healthy fat cell. The center is farther away from an oxygen supply, it sends out bad signals and it can burst and release toxic contents. Large fat cells are associated with insulin resistance, diabetes and inflammation, he added.

Furthermore, the researchers found that the presence of saturated fats or the blockage of ciliary signaling of the FFAR4 receptor does not lead to an increase in the creation of new fat cells from stem cells, but rather the addition of fat to existing cells. Rather than looking how diet correlates with health, we have gone from molecule to receptor to cell to document why healthy fats are beneficial and unhealthy fats contribute to disease, Hilgendorf said. We have provided a mechanism explaining why omega-3 fatty acids are critical for maintaining healthy fat balance and saturated fats should be limited.

The research also may change scientific understanding of how the body manages fat storage in a healthy person. Researchers often talk about the movement of fat in and out of cells, but what we are showing is the importance of stem cell activity in creating new fat cells as being critical for the bodys energy management, said Carl Johnson, a graduate student in the stem cell biology and regenerative medicine program and a co-author of the paper.

Other Stanford co-authors are associate professor of genetics Will Greenleaf, PhD; postdoctoral scholar Anja Mezger, PhD; research engineer Janos Demeter, PhD; and technician Selena Rice.

The research was supported by the National Institutes of Health (grants 5R01GM114276, 5U01CA199216, 5UL1TR00108502, R01 AR054396, DK106404, GM095941. TG2-01159), the Damon Runyon Cancer Research Foundation, the Swedish Research Council, and the Chan-Zuckerberg Biohub.

More:
Omega-3 fatty acids health benefit linked to stem cell... - ScienceBlog.com

Read More...

115 more arazi centres to be set up – The News International

November 24th, 2019 4:46 am

115 more arazi centres to be set up

LAHORE :The Punjab government will set up 115 arazi centres in different districts of the province by the end of the current year to facilitate the general public at their doorstep.

The arazi centres will provide revenue related facilities to the general public in an efficient and transparent manner.

This was stated by Provincial Minister for Revenue Malik Muhammad Anwar while talking to different delegations at his office on Friday.

The minister said that 153 arazi record centres were already providing different facilities to the people in 36 districts of the province.

He said the Board of Revenue was going to procure 20 state-of-the-art mobile vans so that revenue-related facilities could be provided to the people close to their residence.

The BOR has also taken steps to facilitate the rural population and computer technology has been utilised to facilitate the people.

The PTI led government has given special attention to ensuring complete transparency in revenue matters to save public properties from land grabbers, the minister concluded.

Magistrates: A spokesman for the Provincial Industries and Trade Department has the price control magistrates are conducing raids to check the price of essential commodities across the province.

The spokesman stated the price control magistrates conducted raids on 10,350 shops.

As many as 1,952 complaints relating to price-hike were lodged and 189 cases were registered in which 179 persons were arrested and fines amounting to more than Rs3.5 million were also imposed.

PhDs awarded: Punjab University (PU) has awarded PhD degrees to five scholars.

Ambreen Gul, daughter of Mirza Sultan Ahmed, has been awarded PhD in Molecular Biology after approval of her thesis entitled Overexpression of Aspartic Acid in Cotton Against Insects, Ammara Ahad, d/o Abdul Ahad Khan, in Molecular Biology after approval of her thesis entitled Expression of Flavonoid Pigment Related Genes in Cotton (Gossypium hirsutum), Khadija Aaliya, d/o Asif Hussain, Molecular Biology after approval of her thesis entitled Transformation and Expression Studies of Multiple Frost Tolerant Genes in Solanum Tuberosum L, Mehvish Ajaz, d/o Soofi Ajaz Ahmed, in Microbiology and Molecular Genetics after approval of her thesis entitled Azo Dyes Removal by Bacteria Isolated from Industrial Wastewater and Naveed Ahmad Noor, son of Muhammad Nawaz, in the subject of High Energy Physics after approval of his thesis entitled Under Pressure Study of Fundamental Properties of Perovskite Oxides Using Density Functional Theory (DFT).

Link:
115 more arazi centres to be set up - The News International

Read More...

Medical News Today: How do genetic differences affect the risk of bipolar disorder? – Stock Daily Dish

November 24th, 2019 4:46 am

Fresh insights from a recent study of the genetics and biology of bipolar disorder could improve the diagnosis and treatment of the debilitating condition. A new study shows how specific genetic differences affect neural circuits and raise the risk of bipolar disorder as a result.

So concluded the scientists at the Picower Institute for Learning and Memory at Massachusetts Institute of Technology (MIT) in Cambridge who carried out the novel research.

In previous work, they had already shown that a protein called candidate plasticity gene 2 (CPG2) helps to regulate the strength of synapses in brain circuits. Synapses are the connectors through which nerve cells, or neurons, relay chemical signals to each other.

In the more recent research, the investigators found that the brains of people with contained unusually low levels of CPG2.

They also linked specific variants in the gene for CPG2 to dysfunction in synapses. These same genetic differences happen to occur in people with bipolar disorder.

The team reports the findings in a that now features in the journal Molecular Psychiatry.

Its a rare situation, says senior study author Elly Nedivi, who is a professor in the Biology and Brain and Cognitive Sciences departments at MIT, where people have been able to link mutations genetically associated with increased risk of a disorder to the underlying cellular dysfunction.

For bipolar disorder this might be the one and only, she adds.

She and her colleagues are not suggesting that the gene variants that they uncovered actually cause bipolar disorder.

What they are proposing, however, is that having those particular genetic differences could make people more susceptible to bipolar disorder.

In laboratory models, for instance, they sometimes observed synapse dysfunction with combined rather than single variants.

According to the National Institute of Mental Health, around in the United States will have bipolar disorder at some point in their lives.

People with bipolar disorder experience episodes of mania and that bring on extreme shifts in mood, activity levels, and energy.

The episodes are much more severe than the ups and downs that affect most people. They can make it very difficult to carry out daily tasks, get along with people, study, and pursue a career.

Bipolar disorder is a and high rates of death by suicide. Drugs do not always work and not everyone with bipolar will experience complete recovery between episodes.

Prof. Nedivi and her team have been studying synapses for many years.

They discovered that CPG2 influences synaptic strength by helping to regulate the number of receptors for the chemical signals that pass between neurons.

The gene that holds the instructions for making CPG2 is Spectrin Repeat Containing Nuclear Envelope Protein 1 (SYNE1).

On learning that studies had linked variants in SYNE1 to raised risk of bipolar disorder, the team decided to investigate the underlying biology in the light of their own findings about CPG2.

The researchers began by examining postmortem brain tissue from various brain banks.

The samples came from people who had received a diagnosis of bipolar disorder, or other psychiatric conditions that share some of its symptoms, such as or major depression. They also examined samples from individuals who did not have any of these conditions.

The examinations revealed that only brain tissue from people with bipolar disorder contained significantly less CPG2.

The bipolar samples did not show lower levels of other proteins known to play a role in synaptic functions: only CPG2 was lower.

Our findings, the authors write, show a specific correlation between low CPG2 levels and incidence of [bipolar disorder] that is not shared with schizophrenia or major depression patients.

The researchers then used deep-sequencing tools to search for SYNE1 variants in the bipolar brain tissue samples that had shown reduced levels of CPG2.

They focused their efforts on the regions of the gene that control CPG2 expression and therefore the amount that cells produce.

In a separate exercise, they also searched genomic archives to identify variants in CPG2-encoding regions of SYNE1. Differences in this coding can affect the structure and function of the protein.

In experiments with cultured neurons, the team then examined the cellular effects of both types of variants: those in the CPG2 expression-altering region of SYNE1 and those in the coding region for the protein.

The results showed that some expression-altering gene variants had no effect on CPG2 level, while others altered it significantly.

The team also found two examples of paired variants that reduced CPG2 expression but that had no effect as single variants.

There was also a range of results in the experiments with protein-coding variants. These identified SYNE1 differences that altered the structure or function of CPG2 in specific ways.

For instance, one SYNE1 variant reduced the ability of CPG2 to attach to the spines that contain excitatory synapses, while another impaired the cycling of receptors in the synapses.

The findings reveal how specific SYNE1 differences that occur in people with bipolar disorder can upset the function of a protein that plays a key role in the connections in brain circuits.

Further research is now needed to determine how bipolar disorder might develop from such cellular disruptions.

Prof. Nedivi and her team are planning to examine the effect of some of the variants on behavior in animals. They also want to look more closely at some of the disrupted cell processes and how they might fix them.

Alongside these studies, they will continue to investigate human samples to find out more about the specific gene variants and their links to the risk and development of bipolar disorder.

Read the original post:
Medical News Today: How do genetic differences affect the risk of bipolar disorder? - Stock Daily Dish

Read More...

Orf Expression Clones Market Healthy Pace Throughout The Forecast Throughout 2017-2025 – Zebvo

November 24th, 2019 4:46 am

DNA is transcribe into messenger RNA, messenger RNA is translated into protein ORF. During translation, the combination of three nucleotide codons are required for protein synthesis. The nucleotide that starts translation and stops translation is known as ORF. Every DNA has six open reading frame and it is important to determine the correct open reading frame so that the protein is expressed properly. An Open Reading Frame starts with ATG (Met), which is known as start codon and ends with DNA sequence such as TAA, TAG, TGA known as stop codon. ORF clones are eliminates the wearisomesteps of RNA isolation, DNA synthesis, PCR amplification and other tedious sequencing and validation procedures.

To Remain Ahead Of Your Competitors, Request for a Sample Here @https://www.persistencemarketresearch.com/samples/19597

The ORF expression clones are plasmid that contains protein coding DNA, the DNA contains the coding sequence without 5 and 3 end untranslated regions. The ORF expression clones helps to save as it moves directly protein expression and protein analysis. The ORF clones aids to get protein expression and analysis faster. The ORF allows to get gene of interest and expressed protein quickly, and help researchers to conduct clinical and medical applications. Clinical laboratory are highly equipped with assay and instrument systems used for the detection and classification of various disease type such as cancer and risk of cancer progressions, cardiovascular diseases, and others. The advancement in the molecular genetics, bioinformatics, proteomics, increasing number of infection rate is prompting manufacturers to seek newer methods of research, has led to the revenue growth over the forecast period.

Increased demand for research and development for early detection and diagnosis of disease, increased expenditure on healthcare sector, growing number of hospitals and diagnostic laboratories, increased demand for personalized medicines requires the study of individual cell structure and function, rise in prevalence of cell based diseases such as cancer and autoimmune diseases requires the detection and diagnosis of specific cell and tissue, rise in number of biopsy procedures. Technological advancement in the diagnostic and treatment process of infectious diseases, advancement in molecular techniques are the factors fueling the demand of ORF expression clone market in the near future.

The global ORF expression clones market is segmented on basis of expression system,application, end user and geography

Segment by Expression System

Segment by Application

Segment by End User

Global ORF expression clones is segmented by expression system, application and end user. On the basis of expression system the, ORF expression clones market is segmented as mammalian expression system, lentiviral expression system, bacterial expression system, yeast expression system, insect, wheat germ cell and others. Based on the application type, global ORF expression clones market is segmented as recombinant protein expression, functional assays, protein characterization, In vitro transcription and other application for research and study purpose. On the basis of end user, the global ORF expression clones market is segmented into biotechnological companies, pharmaceutical companies, contract research organizations, academic/ research institutes. Increasing outsourcing by pharmaceutical and biotechnological companies, declining R&D productivity and patent cliff sales drop leading to increasing research intensity in the pharmaceuticals sector, rapid process/product development due to fewer steps, increased awareness about new product launch and others are some of the factors drive the global ORF expression clones market during the forecast period. Whereas high cost and short reaction scale, low protein expression, inadequate access to health care, lack of standardized tools for research and development are some of the factors that may hamper the growth of global ORF expression clones market.

By Geography, the global ORF Expression Clones market is segmented into five broad regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America is estimated to lead the global ORF expression clones market due to increasing focus on protein expression and production, growing demand for simple and efficient protein production methods, government funding for research and development in developed countries and others. Europe market is also projected to experience high growth due to emphasis on up-scaling and industrial application in the near future. Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, owing to factors such as focusing on healthcare expenditures, rise in research and development facilities and others.

To Get Extensive Insights On Key Trends, Request For Customization Here @https://www.persistencemarketresearch.com/request-customization/19597

Some of the major players in global ORF expression clones market are Thermo Fisher Scientific, GeneCopoeia, Inc. Dharmacon, Inc., BioCat GmbH, Source BioScience, Kabushiki Kaisha DNAFOR, GenScript, OriGene Technologies, Inc. Sino Biological Inc. Promega Corporation and Others.

Read more here:
Orf Expression Clones Market Healthy Pace Throughout The Forecast Throughout 2017-2025 - Zebvo

Read More...

Medical News Today: Targeting this protein could help combat aging – Stock Daily Dish

November 24th, 2019 4:46 am

Scientists have discovered an unknown genetic mechanism of cell metabolism that becomes increasingly dysfunctional with aging. Is it possible to combat aging?

Researchers at the cole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland suggest that their findings could lead to new targets for treatments to combat aging and age-related conditions.

Their discovery concerns a protein that alters the function of mitochondria, which are the tiny power units inside cells that give them their energy.

The EPFL team found that brain and muscle tissue from aged animals had high levels of the protein, which is called pumilio RNA binding family member 2 (PUM2).

A in the journal Molecular Cell describes how aging induces higher levels of PUM2, which, in turn, reduce levels of another protein called mitochondrial fission factor (MFF).

MFF helps cells break large mitochondria into smaller units and clear them away. The tissue samples from the aged animals also had lower levels of MFF.

The researchers suggest that as animals age, the PUM2/MFF pathway becomes more and more dysregulated.

As PUM2 levels rise, they bring down levels of MFF. The result is that cells become increasingly unable to break up and clear away smaller mitochondria. As time goes by, cells and tissues accumulate more and more large, unhealthy mitochondria.

PUM2 is an RNA-binding protein. These molecules alter gene expression by binding to the messenger RNA (mRNA) molecules that carry DNA code for cells to process.

In the recent study, the team discovered that when PUM2 binds to mRNA molecules that carry the DNA code for MFF, it blocks cells ability to make MFF protein from those mRNA molecules.

Most research on the molecules that influence aging in cells and tissues tends to focus on gene transcription into mRNA. However, this is just the first step in the complex process of transferring information held in genes into the workings of cells.

The EPFL researchers discovered the PUM2/MFF pathway when they decided to investigate the step that occurs after gene transcription.

When they screened animal cells to identify RNA-binding proteins that changed with age, they found that PUM2 was particularly elevated in older animals.

PUM2 binds only to mRNA molecules that have sites that it recognizes. When it attaches to the mRNA, it stops the translation of the code into the corresponding protein.

By employing a systems genetics approach, the team discovered a previously unknown mRNA that PUM2 binds to. This was the mRNA that carries the code for cells to make MFF.

In another part of the study, the researchers demonstrated how it might be possible to reverse the age-related effect of PUM2 on cells and tissues.

Using CRISPR-Cas9 gene-editing technology, they reduced PUM2 in the muscles of old mice by silencing its corresponding encoding gene.

This led to higher levels of MFF protein, which through increased breakup and waste-clearing improved mitochondrial function in the aged mice.

The team also investigated a similar mechanism in the roundworm Caenorhabditis elegans, which is a model that scientists often use to study molecular pathways.

In the roundworm, aging induces higher levels of the RNA-binding protein PUF-8. The researchers found that silencing the corresponding gene for PUF-8 in older worms improved the functioning of their mitochondria and extended their lifespan.

Other studies have linked RNA-binding proteins to neuromuscular degenerative diseases. They have also demonstrated that they often collect into clumps called pathological granules.

The EPFL researchers found that PUM2 has a similar tendency, with aging, to clump into particles that bind and capture MFF mRNA.

Continue reading here:
Medical News Today: Targeting this protein could help combat aging - Stock Daily Dish

Read More...

Feliciano Lopez planning to have children with wife in the future – Tennis World USA

November 24th, 2019 4:45 am

Feliciano Lpez got married to Sandra Gago earlier this year. Asked if they planned to have children, the Spanish player replied: "There are guys who take care of every detail and follow their routines while others travel with their family in tournaments.

I may become a father in a too far away future and I would like my child to come to see me play." On his longevity, Lopez added: "I did not expect to compete at the level I am. Turning 30, many of my friends were getting injured, dropping on the rankings and this age seemed difficult to overcome to me.

I was lucky to have a very good body and genetics to play tennis. It made me suffer a few injuries, so I changed the training regime and I started taking care of my eating regime. For a sportsman, dropping two or three kilos is major and so you start playing better.

Winning the Queen's title at 34 years of age and another time at 37 was very satisfying. I started thinking that it could not happen to me. Feeling competitive physically at this age made me stronger mentally because despite I travel with a physiotherapist that has been taking care of my body for years, I do not recover in the same way after matches.

"You have to handle the kind of sponsor because as a famous person you have a social responsibility. Brands like alcohols or betting companies, you have to be very careful."

Go here to read the rest:
Feliciano Lopez planning to have children with wife in the future - Tennis World USA

Read More...

A Comprehensive Analysis of the Rheumatoid Arthritis Stem Cell Therapy Market Available in the Latest Report – Tech Admirers

November 24th, 2019 4:43 am

Share

Share

Share

Email

With a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global rheumatoid arthritis stem cell therapy market as well as the factors responsible for such a growth. Our highly dedicated professionals have inputted critical and accurate insights associated with every industry, and region by doing thorough primary and secondary research.

We leverage space-age industrial and digitalization tools to provide avant-garde actionable insights to our clients regarding the rheumatoid arthritis stem cell therapy market. For enhancing readers experience, the report starts with a basic overview about the rheumatoid arthritis stem cell therapy market and its classification. Further, we have considered 2028 as the estimated year, 2018 2028 as the stipulated timeframe.

Competitive Assessment

The rheumatoid arthritis stem cell therapy market report includes global as well as emerging players:

The insights for each vendor consists of:

Obtain the Report TOC: https://www.factmr.com/connectus/sample?flag=T&rep_id=1001

Regional Analysis

Important regions covered in the rheumatoid arthritis stem cell therapy market report include:

The rheumatoid arthritis stem cell therapy market report also provides data regarding the key countries in the defined regions.

Segmentation Analysis

By Treatment Type:

By Distribution Channel:

What insights does the rheumatoid arthritis stem cell therapy market report provide to the readers?

Get the Report Sample here: https://www.factmr.com/connectus/sample?flag=S&rep_id=1001

Questionnaire answered in the rheumatoid arthritis stem cell therapy market report include:

The rest is here:
A Comprehensive Analysis of the Rheumatoid Arthritis Stem Cell Therapy Market Available in the Latest Report - Tech Admirers

Read More...

Consumer DNA Testing May Be the Biggest Health Scam of the Decade – Gizmodo

November 24th, 2019 4:42 am

At the start of this decade, the federal government called out consumer DNA testing as a burgeoning scam industry. Little did we know how it would explode in popularity.

In 2010, the U.S. Government Accountability Office (GAO) published an investigative report that bashed consumer DNA test companies for misleading the public. It accused them of deceptively claiming their products could predict the odds of developing more than a dozen medical conditions; some even went as far to offer equally dubious dietary supplements. The report had followed a similar lambasting of the industry by the GAO in 2006.

Also in 2010, the FDA publicly warned 23andMe and other companies that genetic health tests were considered medical devices and needed to be cleared by the FDA before they could be sold to the public. Three years later, following a lack of response from 23andMe, the agency took the harsh step of temporarily banning 23andMe from selling its health-related tests at all.

Despite these hurdles, the DNA testing industry has nonetheless exploded. According to a report by MIT Technology Review this February, more than 26 million people have had their DNA tested by the biggest names in the industry, with AncestryDNA, 23andMe, and MyHeritage being the top three.

Consumer DNA testing is undoubtedly now mainstreambut its not much less scammy than it was when the decade started.

The industry has existed since the late 1990s. But in 2007, the new kid on the block, 23andMe, became the first company to offer a particular kind of at-home DNA test that was cheap, easy to use, and promised to track back your origins further back than ever before.

23andMes testsand eventually those of its competitorssearch for and analyze the most common genetic variations, called single nucleotide polymorphisms (SNPs), in our autosomal DNA, the 22 of 23 pairs of chromosomes not used to determine sex. For as little as $99 and a spit sample, these SNP-based tests are advertised to determine a persons ancestry or genetic health risks. But much of this realm of consumer DNA testing, as the GAO report showed, can uncharitably be described as complete bullshit.

The crux of the problem is that our genetics are only a piece of the puzzle that influences our health. Sure, you can sometimes point to a specific gene mutation that always makes someone sick in a specific way if they carry it. But much more often, its a complex, barely understood mix of gene variants that predispose us to develop cancer or heart diseaseand that risk can be amplified or muted by our environment (including the crucial months we spend in the womb).

In the earliest days, companies didnt much care for this complexity, using weak evidence to make sweeping health claims about which genes ought to make you more of a fish eater or develop diabetes.

Following the FDAs ban in 2013, 23andMe spent the next two years devising genetic health tests that wouldnt overpromise. In 2015, it was allowed to sell tests that told people if they carried a recessive mutation for genetic conditions like Bloom syndrome and sickle-cell disease. A positive test meant their children would have a 25 percent chance of having the condition if both parents were carriers. Two years later, it became the first company with FDA-approved tests that were allowed to tell people about their risk of developing one of 10 diseases or conditions, such as late-onset Alzheimers or celiac disease.

23andMes return to the health side of things wasnt the only fuse that lit a fire under the consumer DNA industrythe tens of millions in annual advertising now being spent by companies like MyAncestry certainly helped, too. But regardless, the FDAs approval of these tests signaled a new opening in the industry. And unsurprisingly, the industry as a whole has ballooned, as has the glut of scammy services on offer.

Many of these companies now steer clear of making blanket health claims, but it doesnt make them any less laughable. Your DNA results can apparently tell you whether youve found your romantic match, how to be good at soccer, and, like a decade ago, how to find the perfect diet and avoid bloating. Just dont pay attention to the studies showing that theres no consistent link between genes seemingly tied to our nutrition and any actual diet-related conditions.

Its not only the tests vaguely connected to our health that are the problem. As Gizmodo once illustrated, even relying on these DNA tests to figure out your ancestry is a dicey proposition. At best, youre roughly estimating where your recent ancestors lived, but that estimate can vary widely depending on which company does the testing, thanks to the different algorithms they use. And the farther away your lineage is from Europe, the less accurate these tests will be for you, thanks to the fact that the algorithmsas well as the research linking genes to our healthare largely based on the DNA of white Americans and Europeans.

Health and ancestry aside, sharing your DNA with the outside world can have unintended consequences. Law enforcement agencies are now using genealogy databases to solve criminal cases, by connecting anonymous crime scene DNA to DNA submitted to these family tree companies, working backward through distant relatives to identify their suspect. And while some people may be fine with this genetic sleuthing, there are no clear rules on how this data can be used by law enforcementtheres merely the promise by private companies that they will share responsibly. This November, police in Florida obtained a warrant to search through a third-party genealogy database, months after the service had enforced a new opt-in policy meant to let users decide if they wanted their data to be searchable by police in these cases.

At a certain point, it wont even matter whether youve decided to share your DNA. A study last October estimated that once enough peoples DNA is in a databasea scant 2 to 3 percent of any given populationanyone could conceivably track the identity of every person in that population using the same techniques genetic detectives are using now. And researchers have already demonstrated how less scrupulous forces, including hackers, could actively manipulate these databases.

None of this is meant to diminish the real potential of genetics as a field of research and medicine, nor the progress that has been made over the past decade.

Companies like 23andMe rely on detecting thousands of genetic markers still only a tiny slice of our DNA. But the technology that allows a persons entire genome to be sequenced has vastly improved, scaling down its costs and upkeep over the past decade. These techniques can scan a persons whole genome as well as the smaller part of the genome that codes for the proteins our bodys cells make, called the exome.

In 2010, for instance, the company Illumina initially offered its whole genome sequencing at $50,000 a person; this year, Veritas dropped the price of its service to only $600 and says it may soon charge as little as $100.

These innovations have led to large-scale research projects that collect genetic data from hundreds of thousands of people at once. Scientists can scour through these large datasets to find new links between our genes, traits, and medical conditions. This research has helped us better understand longstanding questions about our biology and health. Someday soon, genetic sequencing may also help us optimize the existing medical treatments people get, particularly for conditions like cancer.

Right now, though, its still up in the air how useful this info dump really is to the average person looking to stay healthy.

In March, 23andMe debuted (or more accurately, reintroduced) a service that tells people about their genetic risk of type 2 diabetes. Unlike the tests approved by the FDA, it relies on whats known as a polygenic risk score. This adds up the very small contribution of many genetic markers to a particular condition, which combined might be enough to nudge your overall risk upwards.

The trouble is that these markers have little to do with why you get type 2 diabetesyour age or weight play a much bigger role. And even if the test does consider you genetically unlucky (an average risk difference of 5 percent from a typical person), the advice youll get is the same that anyone hoping for a long, healthy life would get: eat more vegetables and exercise more. This test, as well as many of those offered by the hundreds of big and small DNA testing companies on the market, illustrates the uncertainty of personalized consumer genetics.

The bet that companies like 23andMe are making is that they can untangle this mess and translate their results back to people in a way that wont cross the line into deceptive marketing while still convincing their customers they truly matter. Other companies have teamed up with outside labs and doctors to look over customers genes and have hired genetic counselors to go over their results, which might place them on safer legal and medical ground. But it still raises the question of whether people will benefit from the information they get. And because our knowledge of the relationship between genes and health is constantly changing, its very much possible the DNA test you take in 2020 will tell you a totally different story by 2030.

Given how popular at-home DNA testing has become, theres really no sealing the genie back in the bottle. So if you want to get your genetic horoscope read this holiday, dont let me stop you. But its a big decision you should sleep on. After all, once your DNA is out there, theres no going back.

Read this article:
Consumer DNA Testing May Be the Biggest Health Scam of the Decade - Gizmodo

Read More...

Will a Treatment for Alzheimer’s Ever Be Found? – Columbia University Irving Medical Center

November 24th, 2019 4:42 am

In the 90s, Alzheimers researchers were full of optimism. New genetic studies all pointed to one culprithard clumps of protein, called amyloid, that litter the brains of people with the disease.

With the emergence of the first tangible target, pharmaceutical companies jumped in to develop drugs to clear amyloid from the brain. In animals, the drugs appeared to improve memory. But the results of human clinical trials that followed were disheartening: One after one, these drugsall designed to target amyloidhave failed to slow the disease.

The onslaught of news about these failures has left the public wondering whether amyloid has anything to do with Alzheimersand whether a new approach is needed.

The field has already begun to redirect its focus, says Scott Small, MD, director of Columbias Alzheimers Disease Research Center and theBoris and Rose Katz Professor of Neurology at Columbia University Vagelos College of Physicians and Surgeons.

Theres now reason to be cautiously optimismistic, he says, because we have uncovered new pathways that lead to the disease, and we know that they truly make a difference.

The CUIMC Newsroom spoke with Small about the current state of research into Alzheimers treatments and prevention.

In retrospect, the idea that reducing amyloid in the brainwhich all the failed drugs dois based on an incomplete picture of the disease.

To treat a disease, we need to treat whats broken. But its very difficult to find whats broken in these slowly progressive brain disorders.

One way to find whats broken is through genetics, but the first wave of genetic studies in the 80s and 90s only had the technical capabilities to investigate Alzheimers cases that run in families, those caused by a single gene.

The results of these studies all seemed to converge on one biological process: amyloid.

But these single-gene forms of Alzheimers are rareand account for maybe 2% to 3% of cases. Most cases of Alzheimers are caused by a complex interplay of many genes and the environment.

The field made the assumption that amyloid is the primary culprit in all forms of Alzheimers. It made perfect sense, because we see amyloid in all patients with Alzheimers, whether their disease is caused by a single gene or not.The amyloid finding was extremely exciting, and there was a sense that we were on the cusp of curing this devastating, horrible disease.

The amyloid hypothesis is that amyloid is the trigger of everything in Alzheimers. That seems now to be wrong.

New studies from the past decade tell us that amyloid is part of the story of Alzheimers disease, but its the smoke, not the fire. Weve learned that the single-gene and more common, complex forms of Alzheimers are not identical, though they do overlap.

Theres been a lot of backlash against the amyloid hypothesis lately, but in the 90s, it was the right idea. The pharmaceutical industry was right to jump on the amyloid bandwagon. And theyre now right to give it up, I think.

Back in the 80s and 90s, genetic tools weren't quite developed enough to address the real question we had: What genes are involved in most cases of Alzheimers disease?

Techniques have advanced and we can now answer this question. New studiesmany led by Richard Mayeux, MD[chair of neurology at Columbia]have been pointing to other processes in the brain. We also have better biological tools that can reveal the basic problem inside neurons.

Based on this research, the new consensus in the field is that there are two other pathways that cause the disease.

One involves protein trafficking, which is how proteins are shipped to different sites within a single cell. The health of neurons, more so than other cells, depends on protein trafficking in and out of one particular site: the endosome.

In Alzheimers, the flow of proteins out of the endosome is blocked, and we think that causes the other problems we see in the disease: the amyloid, the tau tangles also common in the Alzheimers brain, and the neurodegeneration. Essentially it's a plumbing problem.

Our research here at Columbia provided some early evidence for an endosomal trafficking problem in Alzheimers. And genetic studiesincluding those led by Dr.Mayeuxhave now found that some endosomal genes are linked to Alzheimers, which provides more support.

The second pathway involves microglia, which are cells in the brain that help maintain the health of neurons and help keep the spaces between neurons clear of pathogens, protein aggregates, and other cellular debris.

Recently discovered genesby Phil De Jager, MD, PhD, in our center and otherspoint us to these cells. But what exactly is wrong with the microglia is still hotly debated. We dont know if theyre working too well or not well enough, but we do know theyre not working properly.

We now, I believe, have evidence to help us understand why the first hypothesis was wrong. Scientifically, we have very good justification to argue why our new hypotheses are correct.

Were now seeing that companies are getting back into drug development because these new pathways are so compelling.

In the coming years, our biggest focus at the Alzheimers Disease Research Center at Columbia will be accelerating drug discovery. One of the most important goals is to develop new biomarkersfor the new Alzheimers pathways. These biomarkers are crucial for developing the new generation of theraputic agents.These biomarkers will be useful for enrolling patients into new anticipated clinical trials, following the logic of precision medicine.Also, just as biomarkers of amyloid were important for testing assumptions about the primacyof amyloid in the disease, these biomarkers are important for testingor potentially refutingthe new pathways.

Were also testing gene therapies and other ways to restore endosomal traffickingto see if that prevents neurodegeneration in animal models.

Frank Provenzano and Adam Brickman are developing new techniques, with imaging and cognitive testing, to detect patients with endosomal defects as early as possible. We think the sooner we can treat people, the better. Sabrina Simoes, one of our newest members, is developing new ways to use spinal fluid and blood to remotely monitor endosomal trafficking. Thats a critical step in measuring a drugs effectiveness when the drug moves to clinical testing.

In science, though, you never can be sure.The only way well know were right is by developing drugs and testing the hypothesis in clinical trials in patients, like we did with the amyloid hypothesis.

In my practice, I encounter many people who have family members with Alzheimer's and theyre worried about that their genes. But in most cases, just because your mother has it, doesnt mean youre going to get it.

In a complex disease, each gene and each environmental factor is like putting a pebble on a scale. None of them by themselves can prevent or cause Alzheimers.So if your parent has Alzheimers, that puts one pebble on the scale. But if you went to college, if you exercise, those are pebbles on the other side of the scale.

Many of the things that we thought historically cause Alzheimer's have been debunkedfor example, the idea that itwas caused by various heavy metals. But we do know that maintaining cardiac health is good: Exercise is good; smoking is bad; developing diabetes or obesity increases the risk.These recommendations, as most people know, are true for any disease.

People often ask me this question, hoping I know something that no one else does. I dont have any other answers at the moment, but everyone in the field is doing their best to find new ways to forestall this disease.

Follow this link:
Will a Treatment for Alzheimer's Ever Be Found? - Columbia University Irving Medical Center

Read More...

AI helps identify gene, environment networks that shape personality – Washington University School of Medicine in St. Louis

November 24th, 2019 4:42 am

Visit the News Hub

Personality genes strongly linked to learning, memory

Researchers at Washington University School of Medicine in St. Louis and the University of Granada, Spain, used artificial intelligence techniques to identify gene networks that appear to play a major role in the development of and variation in personality.

Using artificial intelligence techniques, researchers studying the role of genes and the environment in shaping our personalities have identified gene networks largely responsible for the development of and variation in personality.

Those networks include 972 individual genes linked to aspects of personality, such as self-awareness, intentionality which has to do with a person being deliberate or purposeful and creative thinking relating to the purpose and meaning a person hopes to achieve. The findings also suggest that, regardless of genes and environmental factors, individuals still possess the capacity to make choices that also can influence personality and that those choices can result in personality changes over time.

The new research, led by a group at Washington University School of Medicine in St. Louis and the University of Granada, Spain, is published Nov. 21 in the journal Molecular Psychiatry.

Personality is an individuals unique pattern of behaviors, feelings and thoughts, and those factors are strong predictors of physical, mental and social health, said the studys senior investigator, C. Robert Cloninger, MD, a professor emeritus in psychiatry at Washington University. A better understanding of how those factors work together could contribute to improvements in psychiatric and general health for people around the world.

Cloninger

Using computer algorithms, they identified three distinct gene networks connected to personality. The networks are related to learning and memory, but the computer algorithms also found that most of the genes in the three personality networks are not only associated with brain activity but also function in many other organs. As a result, development of a healthy, well-integrated personality may influence a persons physical health as well as his or her mental and social health and well-being, Cloninger said.

In addition to genes, a persons environment which might include home life, family income level, education, exposure to violence or poverty, rural or urban life, and other factors also influences personality, he said. Our personalities develop from the actions of both genetic and environmental factors, as well as interactions between genes, and between genes and environment. Although there are many combinations of genetic and environmental influences, as human beings we still have the capacity to freely choose some aspects of how our personalities develop.

The researchers studied gene-environment relationships in more than 2,100 healthy people in Finland who were part of whats called the Young Finns Study. The scientists then replicated those findings in people from other cultures and backgrounds, studying similar genetic data from more than 900 healthy adults in Germany and more than 1,000 adults in South Korea.

We were able to replicate associations between genetic markers and personality traits in all three groups, said co-investigator Igor Zwir, PhD, an assistant professor in psychiatry and an associate professor in computer science and artificial intelligence at the University of Granada, Spain. In all three populations, we found the same associations between personality traits and genetic markers. However, in people within each country, the same gene networks didnt always lead to the same personality traits.

Zwir

Even with the influence of genes and environmental factors, Cloninger noted that an individuals free will also is involved in how his or her personality develops, as well as how it might change over time.

For a long time, mental health professionals felt that personality traits were fixed early in life and that a persons personality didnt really change much, but weve found that personality can and does change and evolve, he said. Some gene networks influence habit learning, which is the gradual acquisition of associations between stimuli and responses that help us learn to make one choice rather than another. Others influence our capacity to set goals and accomplish them intentionally. But when we change our goals and intentions, or the things we value, we actually also modify the ways that these genes work to influence personality. In other words, our character allows us to regulate the way some of these genes function.

The researchers divided personality into two parts: temperament, representing habits and automatic emotional reactions; and character, representing qualities such as cooperativeness, self-directedness and self-transcendence. The way a person develops his or her character shapes the ability to regulate desires and to satisfy goals and values.

Computer algorithms allowed the researchers to identify clusters of genes related to character that regulate temperament through pathways that involve learning. But in addition to their effects on the brain, those genes also may influence overall health and vulnerability to illness. It turned out the healthiest people were able to create healthy ways of living, using their self-awareness and insight.

The researchers also found that some of both temperament and character were passed on from ones parents. About 50% of a persons temperament and character were heritable. In addition, they found that what was inherited involved three distinct ways of learning that are crucial to being healthy and feeling satisfied with life.

Nature and nurture cannot be separated, Cloninger said. We inherit how we learn, and that means we are then able to deliberately and creatively shape how we adapt to lifes challenges and opportunities.

Added Zwir: Although we inherit some of our personality, that still leaves a great deal of room for change. We are uncovering a dynamic system of relationships between gene networks and environmental factors. If you measure personality with our tools and then come back and do it again six months or a year later, you might see changes because personality seems to develop and evolve. Very little of this is fixed. It can be changed in both positive and negative ways.

Zwir I, et al. Three genetic-environmental networks for human personality. Molecular Psychiatry, published online Nov. 21, 2019. https://doi.org/10.1038/s41380-019-0579-x

Also see Cloninger CR, et al. The complex genetics and biology of human temperament: A review of traditional concepts in relation to new molecular findings. Translational Psychiatry, published online Nov. 11, 2019. https://doi.org/10.1038/s41398-019-0621-4

The Young Finns Study was financially supported by the Academy of Finland; the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals, the Juho Vainio Foundation; the Paavo Nurmi Foundation, the Finnish Foundation for Cardiovascular Research; the Finnish Cultural Foundation; the Tampere Tuberculosis Foundation; the Emil Aaltonen Foundation; the Yrjo Jahnsson Foundation; the Signe and Ane Gyllenberg Foundation; the Diabetes Research Foundation of the Finnish Diabetes Association; an EU Horizon 2020 grant; and the Tampere University Hospital Supporting Foundation. The American Foundation for Suicide Prevention supported the study of healthy Germans. The national Healthy Twin Family Register of Korea supported the study of healthy Koreans. In addition, the Anthropedia Foundation and the Spanish Ministry of Science and Technology supported the collaboration.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read the original post:
AI helps identify gene, environment networks that shape personality - Washington University School of Medicine in St. Louis

Read More...

Page 798«..1020..797798799800..810820..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick